DE69812100T2 - Adenosin enthaltendes arzneimittel - Google Patents

Adenosin enthaltendes arzneimittel

Info

Publication number
DE69812100T2
DE69812100T2 DE69812100T DE69812100T DE69812100T2 DE 69812100 T2 DE69812100 T2 DE 69812100T2 DE 69812100 T DE69812100 T DE 69812100T DE 69812100 T DE69812100 T DE 69812100T DE 69812100 T2 DE69812100 T2 DE 69812100T2
Authority
DE
Germany
Prior art keywords
product containing
medicinal product
containing adenosine
adenosine
weakened
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69812100T
Other languages
English (en)
Other versions
DE69812100D1 (de
Inventor
Ilan Cohn
Pnina Fishman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DE69812100D1 publication Critical patent/DE69812100D1/de
Publication of DE69812100T2 publication Critical patent/DE69812100T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69812100T 1997-07-10 1998-07-10 Adenosin enthaltendes arzneimittel Expired - Fee Related DE69812100T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12127297A IL121272A (en) 1997-07-10 1997-07-10 Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
PCT/IL1998/000324 WO1999002143A2 (en) 1997-07-10 1998-07-10 Medicament comprising adenosine

Publications (2)

Publication Number Publication Date
DE69812100D1 DE69812100D1 (de) 2003-04-17
DE69812100T2 true DE69812100T2 (de) 2003-07-10

Family

ID=11070366

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69812100T Expired - Fee Related DE69812100T2 (de) 1997-07-10 1998-07-10 Adenosin enthaltendes arzneimittel

Country Status (8)

Country Link
US (1) US6911435B1 (de)
EP (1) EP0994702B1 (de)
JP (1) JP2001509479A (de)
AT (1) ATE234082T1 (de)
AU (1) AU8239298A (de)
DE (1) DE69812100T2 (de)
IL (1) IL121272A (de)
WO (1) WO1999002143A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790839B2 (en) 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
IL131096A (en) 1999-07-26 2004-09-27 Can Fite Technologies Ltd Method for preparing a composition derived from muscle tissue
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
ATE299593T1 (de) * 2000-11-07 2005-07-15 Advanced Gene Technology Corp Verfahren zum screenen von pflanzenextrakten nach wirkstoffen
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
US20060134779A1 (en) * 2004-03-10 2006-06-22 Banes Albert J Modulation of cell intrinsic strain to control cell modulus, matrix synthesis, secretion, organization, material properties and remodeling of tissue engineered constructs
JP2005289837A (ja) * 2004-03-31 2005-10-20 Juntendo 骨髄細胞誘導剤の製造方法及び製造装置
WO2008154532A1 (en) * 2007-06-11 2008-12-18 California Pacific Medical Center Method and kit for dynamic gene expression monitoring
US9186406B2 (en) * 2007-08-16 2015-11-17 The Henry M. Jackson Foundation for Advancement of Military Medicine, Inc. Compositions containing nucleosides and manganese and their uses
CN102172359A (zh) * 2011-03-02 2011-09-07 张始状 腺苷与核苷组合在制备治疗肿瘤药物中的应用
TR201809040T4 (tr) 2011-03-21 2018-07-23 Vivolux Ab Solid tümörlerin tedavisi.
BR112015006370B1 (pt) 2012-09-21 2022-04-12 Vivolux Ab Composto citotóxico, sal farmaceuticamente aceitável do mesmo, mistura, composição farmacêutica e uso do referido composto
WO2016051396A1 (en) * 2014-09-30 2016-04-07 Susan Eve Vecht-Lifshitz Pharmaceutical compositions for treating ebola virus disease

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB797237A (en) * 1955-07-26 1958-06-25 Sterling Drug Inc Composition for reducing period of anesthesia
US4364922A (en) * 1980-10-14 1982-12-21 University Of Virginia Alumni Patents Foundation Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4673563A (en) * 1980-10-14 1987-06-16 The University Of Virginia Alumni Patents Foundation Adenosine in the treatment of supraventricular tachycardia
AU8379182A (en) * 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
US5104859A (en) * 1985-09-24 1992-04-14 Solimedco Aktiebolag Continuous administration of adenosine to reduce pulmonary vascular resistance
US5231086A (en) * 1985-09-24 1993-07-27 Item Development Aktiebolag Continuous administration adenosine to increase myocardial blood flow
US5449665A (en) * 1985-09-24 1995-09-12 Item Development Aktiebolag Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5677290A (en) * 1990-05-10 1997-10-14 Fukunaga; Atsuo F. Therapeutic use of adenosine compounds as surgical anesthetics
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
WO1994017809A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine deaminase inhibitor therapies
SE9301324D0 (sv) * 1993-04-21 1993-04-21 Item Development Ab New method of treatment
US5686114A (en) * 1995-06-02 1997-11-11 University Of Iowa Research Foundation Uses of inorganic pyrophosphates
NZ331434A (en) 1998-08-19 2001-02-23 Sullivan & Haddon Group Ltd Elongate building materials such as metal beams, bars and tubes, and process for making them
US20020037871A1 (en) * 1999-01-07 2002-03-28 Pnina Fishman Pharmaceutical use of adenosine agonists
IL127947A0 (en) * 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6790839B2 (en) * 1999-01-07 2004-09-14 Can-Fite Biopharma Ltd. Pharmaceutical administration of adenosine agonists
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
AU2001280946A1 (en) * 2000-08-01 2002-02-13 University Of Virginia Patent Foundation Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis

Also Published As

Publication number Publication date
US6911435B1 (en) 2005-06-28
DE69812100D1 (de) 2003-04-17
AU8239298A (en) 1999-02-08
ATE234082T1 (de) 2003-03-15
WO1999002143A2 (en) 1999-01-21
IL121272A (en) 2000-06-01
EP0994702A2 (de) 2000-04-26
WO1999002143A3 (en) 1999-08-12
IL121272A0 (en) 1998-01-04
JP2001509479A (ja) 2001-07-24
EP0994702B1 (de) 2003-03-12

Similar Documents

Publication Publication Date Title
ATE234082T1 (de) Adenosin enthaltendes arzneimittel
DE60038104D1 (de) Arzneimittelzubereitungen für die behandlung von alpha-galactosidase a-mangel
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
BR9206631A (pt) Sistema de maior penetração na pele para melhor administração tópica de medicamentos
FI863664A0 (fi) Emulsionskompositioner foer dosering av i vatten svaorloesliga joniserbara hydrofoba laekemedel.
ES2053198T3 (es) Sistema de suministro de un farmaco de glucano y adyuvante.
IS2537B (is) Lyfjablanda til inngjafar um húð
NO20001087L (no) Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer
BG101118A (en) Therapeutical compounds
ES2144054T3 (es) Complejos de tri(platino).
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
DK0855916T3 (da) Farmaceutisk præparat indeholdende en Activin-stimulator
DK0825865T3 (da) Transdermalt, terapeutisk system for administrering af testosteron eller testosteronderivat
NO892764L (no) Medikamentell administreringsform for droevtyggere.
WO1999018941A3 (en) Ih-MODULATORS
PL326629A1 (en) Application of flupyrtin in prophylaxy and therapy of deseases associated with damaged hematopoietic cellular system
IT8519907A0 (it) Prodotto farmaceutico cosmetico, in particolare per la cura di acne e seborrea.
PT1144420E (pt) Fosfatidilinositois sulfatados a sua preparacao e a sua utilizacao
SE9000207L (sv) Laekemedel samt anvaendningen av detsamma
IT8448710A1 (it) Riduzione degli effetti tossici causati da farmaci antrachinonici
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE50005282D1 (de) Medikament sowie aufeinander abgestimmte kombination von medikamenten
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
FR2694292B1 (fr) Dérivés de benzimidazole-2-thione-, leur préparation et leur application en tant que médicament.
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee